UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): May 7, 2025~~ 1934

Date of Report (Date of earliest event reported): July 21, 2025

LANTHEUS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36569	~~001-36569~~	35-2318913	~~35-2318913~~
(State or other jurisdictionof incorporation)		(CommissionFile Number)		(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)		(IRS Employer Identification No.)

201 Burlington Road, South Building, Bedford, MA						01730
(Address of principal executive offices)						(Zip Code)

201 Burlington Road, South Building

Bedford, Massachusetts 01730

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (978) 671-8001

Not Applicable ~~(Former name or former address, if changed since last report.)~~

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		TradingSymbol(s)	~~Trading Symbol(s)~~	Name of each exchangeon which registered		~~Name of each exchange on which registered~~
Common stock, par value $0.01 per share		LNTH	~~LNTH~~	The Nasdaq Global Market		~~The Nasdaq Global Market~~

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.~~02. Results~~01 Completion of ~~Operations~~Acquisition ~~and~~or ~~Financial~~Disposition ~~Condition.~~of Assets.

OnAs ~~May 7,~~previously ~~2025,~~announced by Lantheus Holdings, Inc. (“Lantheus” or the “Company”) ~~announced~~on ~~via~~January 12, ~~press~~2025, ~~release~~Lantheus ~~its~~Medical ~~financial~~Imaging, ~~results~~Inc., asa ofDelaware corporation and ~~for~~a subsidiary of the ~~three~~Company, ~~months~~and ~~ended~~Lantheus ~~March~~Radiopharmaceuticals 31UK Limited, ~~2025. A~~a ~~copy~~private limited liability company incorporated under the laws of ~~that~~England ~~press~~(the ~~release~~“Purchaser”), isentered ~~being~~into ~~furnished~~a asSale ~~Exhibit~~and ~~99.1~~Purchase Agreement (the “Agreement”) with Life Medical Group Limited, a private limited liability company incorporated under the laws of England (the “Seller”), and isLife ~~hereby~~Healthcare Group Holdings Limited, a public limited liability company incorporated byunder ~~reference~~the laws of South Africa, pursuant to which the Purchaser would acquire the entire issued share capital of Life Molecular Imaging Limited (“Life Molecular”) (the “Transaction”).

~~The~~On ~~information furnished pursuant to this Item~~July ~~2.02~~21, ~~including Exhibit 99.1~~2025, ~~shall~~the ~~not~~parties becompleted ~~deemed~~the ~~“filed”~~Transaction ~~for~~pursuant ~~purposes~~to ~~of Section 18 of~~ the ~~Securities~~Agreement. ~~Exchange~~In ~~Act~~accordance ofwith ~~1934, as amended (~~the ~~“Exchange Act”)~~Agreement, orupon ~~otherwise~~the ~~subject~~closing toof the ~~liabilities~~Transaction, ~~under~~the ~~that~~Purchaser ~~Section~~paid ~~and~~the ~~shall~~Seller ~~not~~an beupfront ~~deemed~~cash topayment beof ~~incorporated~~$350 million by(following ~~reference~~applicable ~~into~~purchase ~~any~~price ~~filing~~adjustments ofunder the ~~Company~~Agreement) ~~under~~in ~~the~~exchange ~~Securities~~for ~~Act~~all of ~~1933,~~the asoutstanding ~~amended,~~share orcapital ~~the~~of ~~Exchange~~Life ~~Act~~Molecular.

~~Item 9~~The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which was filed as Exhibit 10.~~01. Financial~~37 ~~Statements~~to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and ~~Exhibits~~Exchange Commission on February 26, 2025.

Item 7.01

Regulation FD Disclosure.

On July 22, 2025, the Company issued a press release announcing the completion of the Transaction, as well as the appointment of Dr. Ludger Dinkelborg as the Company’s Head of Research and Development, effective as of August 1, 2025. Dr. Dinkelborg will lead and oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers Solutions and will report directly to the Company’s Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this item and Exhibit 99.1 are not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall this item or Exhibit 99.1 be incorporated by reference into the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such future filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description	~~Description~~
99.1*		Press release of Lantheus Holdings, Inc. dated May 7, 2025, entitled "Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update"
99.1	Press Release, dated July 22, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	~~Cover Page Interactive Data File (embedded within the Inline XBRL document)~~

* Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS HOLDINGS, INC. By: /s/ Daniel M. Niedzwiecki Name: Daniel M. Niedzwiecki Title: Chief Administrative Officer and General Counsel

Date: ~~May~~July 722, 2025

Filing Compare · Lantheus Holdings, Inc.